Tyra Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Tyra Biosciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-23.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-23.6%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Oct 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Jul 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Mar 31

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Dec 15

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: TYRA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: TYRA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Tyra Biosciences Piyasaya Karşı Temettü Getirisi

TYRA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (TYRA)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (TYRA) (3 yıla kadar)	0%

Önemli Temettü: TYRA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, TYRA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: TYRA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: TYRA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Tyra Biosciences Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Chief Financial Officer recently bought US$152k worth of stock

Now 22% undervalued after recent price drop

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences Reports Interim Clinical Proof-Of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

New major risk - Revenue and earnings growth

Co-Founder notifies of intention to sell stock

Price target increased by 8.2% to US$28.50

Co-Founder notifies of intention to sell stock

Price target increased by 9.8% to US$27.67

Now 20% undervalued

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Now 21% overvalued after recent price rise

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Now 22% overvalued after recent price rise

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Price target increased by 7.7% to US$25.20

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 3000E Value Index

Insufficient new directors

Now 29% overvalued

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. Announces Board Changes

Tyra Biosciences, Inc., Annual General Meeting, May 29, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$24.20

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. announced that it expects to receive $200 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC

New minor risk - Share price stability

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Tyra Biosciences, Inc. Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

Price target decreased by 9.0% to US$22.20

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Price target increased by 8.4% to US$24.40

Tyra Biosciences Announces Fda Orphan Drug Designation for Tyra-300 for the Treatment of Achondroplasia

Co-Founder exercised options and sold US$286k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Co-Founder & COO exercised options and sold US$350k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.3% to US$19.25

Tyra Biosciences, Inc. Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300

High number of new directors

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$20.00

Tyra Biosciences Announces Chief Financial Officer Changes

Tyra Biosciences, Inc. Announces Appointment of Ali Fawaz as General Counsel and Secretary

Tyra Biosciences GAAP EPS of -$0.36

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 2000 Growth Index

High number of new directors

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

High number of new directors

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Tyra Biosciences, Inc. has completed an IPO in the amount of $172.8 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin